Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics Spectra BioPhotonics EuroPhotonics Vision Spectra Photonics Showcase Photonics ProdSpec Photonics Handbook
More News

AngioDynamics Acquires Eximo Medical

Facebook Twitter LinkedIn Email Comments
LATHAM, N.Y., Oct. 4, 2019 — AngioDynamics has acquired Eximo Medical and its proprietary 355-nm wavelength laser technology platform. The transaction came in a $46 million upfront consideration with up to $20 million of contingent consideration related to certain technical and revenue milestones. The transaction is being funded exclusively through the use of cash on hand.

The transaction expands AngioDynamics’ existing Vascular Interventions and Therapies (VIT) product portfolio by adding Eximo’s proprietary laser technology, which has received 510(k) clearance for use in the treatment of peripheral artery disease.

Eximo’s laser technology delivers short, high-powered pulses in 355-nm wavelength without compromising the integrity of its fiber optic cables during atherectomy procedures. The technology addresses the risk of perforation through tissue selectivity, addresses the risk of embolization to the patient through the availability of aspiration, and is indicated to provide treatment for in-stent restenosis, which is the gradual renarrowing of the artery after a blockage has been previously treated with a stent.

Angiodynamics is a provider of minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products.

Photonics.com
Oct 2019
BusinessacquisitionsBiophotonicslasers

Comments
back to top
Facebook Twitter Instagram LinkedIn YouTube RSS
©2019 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA, info@photonics.com

Photonics Media, Laurin Publishing
x We deliver – right to your inbox. Subscribe FREE to our newsletters.
We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.